We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
The positive results of the world’s first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in this week’s edition of Nature Medicine.
A pioneering clinical trial for people with a sleep disorder who are at higher risk of developing Parkinson’s has recruited its first UK participant from the Discovery Cohort study at the Oxford Parkinson’s Disease Centre (OPDC)
